日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer

AZD4635联合度伐利尤单抗或奥莱克鲁单抗治疗转移性去势抵抗性前列腺癌患者的II期研究

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-024-03640-6
Falchook, Gerald S; Reeves, James; Gandhi, Sunil; Spigel, David R; Arrowsmith, Edward; George, Daniel J; Karlix, Janet; Pouliot, Gayle; Hattersley, Maureen M; Gangl, Eric T; James, Gareth D; Thompson, Jeff; Russell, Deanna L; Patel, Bhavickumar; Kumar, Rakesh; Lim, Emerson
肿瘤
前列腺癌
肿瘤免疫
发表日期：2024
文献求助 收藏

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

AZD5153（一种溴结构域蛋白4的小分子抑制剂）在复发/难治性恶性实体瘤和淋巴瘤患者中的首次人体研究

期刊:Molecular Cancer Therapeutics
影响因子:5.5
doi:10.1158/1535-7163.MCT-23-0065
Hamilton, Erika P; Wang, Judy S; Oza, Amit M; Patel, Manish R; Ulahannan, Susanna V; Bauer, Todd; Karlix, Janet L; Zeron-Medina, Jorge; Fabbri, Giulia; Marco-Casanova, Paola; Moorthy, Ganesh; Hattersley, Maureen M; Littlewood, Gillian M; Mitchell, Patrick; Saeh, Jamal; Pouliot, Gayle P; Moore, Kathleen N
淋巴瘤
发表日期：2023
文献求助 收藏

Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

AZD4635（一种腺苷A2A受体拮抗剂）单药治疗或联合度伐利尤单抗治疗实体瘤患者的Ia/b期、开放标签、多中心研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-22-0612
Lim, Emerson A; Bendell, Johanna C; Falchook, Gerald S; Bauer, Todd M; Drake, Charles G; Choe, Jennifer H; George, Daniel J; Karlix, Janet L; Ulahannan, Susanna; Sachsenmeier, Kris F; Russell, Deanna L; Moorthy, Ganesh; Sidders, Ben S; Pilling, Elizabeth A; Chen, Huifang; Hattersley, Maureen M; Das, Mayukh; Kumar, Rakesh; Pouliot, Gayle P; Patel, Manish R
信号转导
发表日期：2022
文献求助 收藏